Loading company
Kyverna Therapeutics, Inc.
KYTX · Nasdaq · ·
Next earnings: November 11, 2026
$6.85+0.3%Sep 29 close
- 1M
- -18.2%
- 6M
- -9.6%
- 1Y
- +14.2%
KYTX · Nasdaq · ·
Next earnings: November 11, 2026
$6.85+0.3%Sep 29 close
Kyverna Therapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$38.3M | -$42.1M | +8.94% |
| Profit per share | -$0.63 | -$0.97 | +35.05% |
| Free Cash Flow | -$33.5M | -$37.6M | +10.82% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Kyverna Therapeutics, Inc. has no earnings call transcript available.
“Kyverna continues to advance our rolling BLA submission for stiff person syndrome, progress commercial launch readiness activities and accelerate enrollment in our registrational trial in generalized myasthenia gravis, while advancing our pipeline,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
(mivocabtagene autoleucel, KYV-101) Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation, uniquely designed for potency and tolerability, which is under investigation for B-cell-driven autoimmune diseases. With a single administration, miv-cel has potential to achieve deep B-cell depletion and immune system reset to deliver durable, drug-free, disease-free remission in autoimmune diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Kyverna Therapeutics, Inc.’s Item 2.02 8-K filed August 11, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.